Top

Clinical Rheumatology

Published in:

01-01-2020 | Systemic Sclerosis | Original Article

Malnutrition, associated clinical factors, and depression in systemic sclerosis: a cross-sectional study

Authors: İpek Türk, Nihan Cüzdan, Volkan Çiftçi, Didem Arslan, Muharrem Cem Doğan, İlker Unal

Published in: Clinical Rheumatology | Issue 1/2020

Abstract

Introduction

The aim of this study was to evaluate the associations between malnutrition and the clinical features of the disease and depression in patients with systemic sclerosis (SSc).

Method

Patients with SSc who were followed up in our clinic were enrolled in the study. Malnutrition risk was assessed using the Malnutrition Universal Screening Tool (MUST). Skin involvement was assessed using the modified Rodnan skin score (mRSS) and interincisal distance (ID) measurements were used to assess the maximal mouth opening capacity. The Beck Depression Inventory (BDI) was used for measuring the severity of depression.

Results

Ninety-eight patients with SSc (84.7% women; mean age 52.67 ± 11.26 years) were included in the study. According to the MUST scores, 61.2%, 15.3%, and 23.5% of patients had low, medium, and high risk for malnutrition, respectively. The mRSS was significantly higher in the group with high malnutrition risk compared with low-risk group (p = 0.014). Malnutrition risk was associated with interstitial lung disease and bowel involvement (p = 0.044 and p = 0.021, respectively). Interincisal distance was lower in the group with high malnutrition risk compared with the low-risk group (p = 0.003). Malnutrition risk was higher in patients who had mild-to-severe depressive symptoms than in those without (p = 0.012). Interincisal distance and bowel involvement were the most relevant factors for malnutrition.

Conclusions

The risk of malnutrition is increased in patients with SSc. In our study, microstomia and bowel involvement were the most relevantly associated factors with malnutrition.

Key Points

• The risk of malnutrition is increased in patients with systemic sclerosis (SSc).

• Microstomia and bowel involvement are found to be the most important factors associated with malnutrition.

• Depressive symptoms are seen frequently among patients with SSc, and depression seems to be one of the etiologic factors or the result of malnourishment in SSc.

• Assessment of nutritional status and the presence of depression should be a part of routine clinical visits of patients with SSc.

Stratton RJ, Hackston A, Longmore D, Dixon R, Price S, Stroud M, King C, Elia M (2004) Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the ‘malnutrition universal screening tool’ (‘MUST’) for adults. Br J Nutr 92:799–808PubMed

Baron M, Hudson M, Steele R; Canadian Scleroderma Research Group (2009) Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. J Rheumatol 36(12):2737–2743PubMed

Codullo V, Cereda E, Crepaldi G, Cappello S, Montecucco C, Caccialanza R, Caporali R (2015) Disease-related malnutrition in systemic sclerosis: evidences and implications. Clin Exp Rheumatol 33:190–194

Krause L, Becker MO, Brueckner CS, Bellinghausen CJ, Becker C, Schneider U, Haeupl T, Hanke K, Hensel-Wiegel K, Ebert H, Ziemer S, Ladner UM, Pirlich M, Burmester GR, Riemekasten G (2010) Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis. Ann Rheum Dis 69(11):1951–1957PubMed

Harrison E, Herrick AL, McLaughlin JT, Lal S (2012) Malnutrition in systemic sclerosis. Rheumatology (Oxford) 51(10):1747–1756

Baron M, Bernier P, Côté LF, Delegge MH, Falovitch G, Friedman G, Gornitsky M, Hoffer J, Hudson M, Khanna D, Paterson WG, Schafer D, Toskes PP, Wykes L (2010) Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. Clin Exp Rheumatol 28:42–46

McFarlane IM, Bhamra MS, Kreps A et al (2018) Gastrointestinal manifestations of systemic sclerosis. Rheumatology (Sunnyvale) 8(1):235

Gyger G, Baron M (2015) Systemic sclerosis: gastrointestinal disease and its management. Rheum Dis Clin N Am 41(3):459–473

Crincoli V, Fatone L, Fanelli M, Rotolo R, Chialà A, Favia G, Lapadula G (2016) Orofacial manifestations and temporomandibular disorders of systemic scleroderma: an observational study. Int J Mol Sci 17(7):1189–1201PubMedCentral

10.

Bolster MB, Silver RM (2011) Clinical features of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weismann MH (eds) Rheumatology, 5th edn. Mosby, Philadelphia, p 1383

11.

Baubet T, Ranque B, Taïeb O, Bérezné A, Bricou O, Mehallel S, Moroni C, Belin C, Pagnoux C, Moro MR, Guillevin L, Mouthon L (2011) Mood and anxiety disorders in systemic sclerosis patients. Presse Med 40(2):111–119

12.

Thombs BD, Fuss S, Hudson M, Schieir O, Taillefer SS, Fogel J, Ford DE, Baron M, Canadian Scleroderma Research Group (2008) High rates of depressive symptoms among patients with systemic sclerosis are not explained by differential reporting of somatic symptoms. Arthritis Rheum 59(3):431–437PubMed

13.

Van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755PubMed

14.

LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Cleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed

15.

Furst DE, Clements PJ, Steen VD et al (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25:84–88PubMed

16.

Torok KS, Baker NA, Lucas M, Domsic RT, Boudreau R, Medsger TA Jr (2010) Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis. Clin Exp Rheumatol 28:28–36

17.

Guillevin L, Hunsche E, Denton CP, Krieg T, Schwierin B, Rosenberg D, Matucci-Cerinic M, DUO Registry Group (2013) Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. Clin Exp Rheumatol 31:71–80PubMed

18.

Bartoli F, Fiori G, Braschi F, Amanzi L, Bruni C, Blagojevic J, Bellando-Randone S, Cometi L, de Souza Mueller C, Guiducci S, Rasero L, Epifani F, Furst DE, Matucci-Cerinic M (2016) Calcinosis in systemic sclerosis: subsets, distribution and complications. Rheumatology (Oxford) 55:1610–1614

19.

Tolosa-Vilella C, Morera-Morales ML, Simeón-Aznar CP, Marí-Alfonso B, Colunga-Arguelles D, Callejas_Rubio JL, Rubio-Rivas M, Freire-Dapena M, Guillén-del Castillo A, Iniesta-Arandia N, Castillo-Palma MJ, Egurbide-Arberas M, Trapiellla-Martínez L, Vargas-Hitos JA, Todolí-Parra JA, Rodriguez-Carballeira M, Marin-Ballvé A, Pla-Salas X, Rios-Blanco JJ, Fonollosa-Pla V (2016) Digital ulcers and cutaneous subsets of systemic sclerosis: clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. Semin Arthritis Rheum 46:200–208PubMed

20.

Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 66:754–763PubMedPubMedCentral

21.

Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21:42–46

22.

Wood GD, Branco JA (1979) A comparison of three methods of measuring maximal opening of the mouth. J Oral Surg 37:175–177PubMed

23.

Yao K-T, Lin C-C, Hung C-H (2009) Maximum mouth opening of ethnic Chinese in Taiwan. J Dent Sci 4:40–44

24.

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571PubMed

25.

Hisli N (1989) The validity and reliability of the Beck Depression Inventory among university students. Turk J Psychol 7:3–13

26.

Matsuura E, Ohta A, Kanegae F, Haruda Y, Ushiyama O, Koarada S, Togashi R, Tada Y, Suzuki N, Nagasawa K (2003) Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol 30(8):1782–1787PubMed

27.

Preis E, Franz K, Siegert E, Makowka A, March C, Riemekasten G, Cereda E, Norman K (2018) The impact of malnutrition on quality of life in patients with systemic sclerosis. Eur J Clin Nutr 72(4):504–510PubMed

28.

Caporali R, Caccialanza R, Bonino C, Klersy C, Cereda E, Xoxi B, Crippa A, Rava ML, Orlandi M, Bonardi C, Cameletti B, Codullo V, Montecucco C (2012) Disease-related malnutrition in outpatients with systemic sclerosis. Clin Nutr 31(5):666–671PubMed

29.

Caimmi C, Caramaschi P, Venturini A, Bertoldo E, Vantaggiato E, Viapiana O, Ferrari M, Lippi G, Frulloni L, Rossini M (2018) Malnutrition and sarcopenia in a large cohort of patients with systemic sclerosis. Clin Rheumatol 37(4):987–997PubMed

30.

Nazarinia MA, Esmaeilzadeh E, Emami Y, Salehi A (2016) One decade distinct features, morbidity and mortality of scleroderma: a cross-sectional study. Clin Exp Rheumatol 100(5):74–78

31.

Steen V, Denton CP, Pope JE, Matucci-Cerinic M (2009) Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 48:19–24

32.

Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C, RAPIDS-1 Study Group (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993PubMed

33.

Delano MJ, Moldawer LL (2006) The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract 21(1):68–81PubMed

34.

Baccioglu A, Gulbay BE, Acıcan T (2014) Body composition in patients with stable chronic obstructive pulmonary disease: comparison with malnutrition in healthy smokers. Eurasian J Med 46(3):169–175PubMedPubMedCentral

35.

Laaban JP, Kouchakji B, Dore MF, Orvoen-Frija E, David P, Rochemaure J (1993) Nutritional status of patients with chronic obstructive pulmonary disease and acute respiratory failure. Chest 103(5):1362–1368PubMed

36.

Calanas-Continente AJ, Cervero Pluvins C, Munoz Gomariz E et al (2002) Prevalence of malnutrition among candidates for lung transplantation. Nutr Hosp 17:197–203PubMed

37.

Amin K, Clarke A, Sivakumar B, Puri A, Fox Z, Brough V, Denton CP, Peter EM, Butler P (2011) The psychological impact of facial changes in scleroderma. Psychol Health Med 16:304–312PubMed

38.

Baron M, Hudson M, Tatibouet S, Steele R, Lo E, Gravel S, Gyger G, El Sayegh T, Pope J, Fontaine A, Masetto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira G, Robinson D, Fritzler M, Gornitsky M (2015) Relationship between disease characteristics and orofacial manifestations in systemic sclerosis: Canadian Systemic Sclerosis Oral Health Study III. Arthritis Care Res 67:681–690

39.

Thombs BD, Taillefer SS, Hudson M, Baron M (2007) Depression in patients with systemic sclerosis: a systematic review of the evidence. Arthritis RheumAug 57(6):1089–1097

40.

Roca RP, Wigley FM, White B (1996) Depressive symptoms associated with scleroderma. Arthritis Rheum 39(6):1035–1040PubMed

41.

Faezi ST, Paragomi P, Shahali A, Akhlaghkhah M, Akbarian M, Akhlaghi M, Kheirandish M, Gharibdoost F (2017) Prevalence and severity of depression and anxiety in patients with systemic sclerosis: an epidemiologic survey and investigation of clinical correlates. J Clin Rheumatol 23(2):80–86PubMed

42.

Thombs BD, Jewett LR, Kwakkenbos L, Hudson M, Baron M; Canadian Scleroderma Research Group (2015) Major depression diagnoses among patients with systemic sclerosis: baseline and one-month follow up. Arthritis Care Res 67(3):411–416

43.

Haythornthwaite JA, Heinberg LJ, McGuire L (2003) Psychologic factors in scleroderma. Rheum Dis Clin N Am 29(2):427–439

44.

Thombs BD, Hudson M, Taillefer SS, Baron M, Canadian Scleroderma Research Group (2008) Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthritis Rheum 59(4):504–509PubMed

45.

Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, Mayes MD, Clements PJ, Khanna D (2011) Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology (Oxford) 50(2):330–334

46.

Naidoo I, Charlton KE, Esterhuizen TM, Cassim B (2015) High risk of malnutrition associated with depressive symptoms in older South Africans living in KwaZulu-Natal, South Africa: a cross-sectional survey. J Health Popul Nutr 19:33

47.

Roelofs J, van Breukelen G, de Graaf LE, Beck AT, Arntz A, Huibers MJH (2013) Norms for the Beck Depression Inventory (BDI-II) in a large Dutch community sample. J Psychopathol Behav Assess 35:93–98

Title: Malnutrition, associated clinical factors, and depression in systemic sclerosis: a cross-sectional study
Authors: İpek Türk
Nihan Cüzdan
Volkan Çiftçi
Didem Arslan
Muharrem Cem Doğan
İlker Unal
Publication date: 01-01-2020
Publisher: Springer London
Keywords: Systemic Sclerosis
Mood Disorders
Malnutrition
Affective Disorder
Published in: Clinical Rheumatology / Issue 1/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-019-04598-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Method

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 1/2020

The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review

Association of radiographic findings in hand X-ray with clinical features and autoantibodies in patients with systemic sclerosis

Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry

Rheumatoid arthritis and neurodegenerative dementia: a nested case-control study and a follow-up study using a national sample cohort

Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study

Hypouricemia: what the practicing rheumatologist should know about this condition

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials